1. Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)
- Author
-
Misaki Tokunaga, Ai Takahashi, Sachiko Hayakawa, Hiroaki Hino, Daisuke Kikuchi, Taku Obara, Misato Ito, Yoshiteru Watanabe, Ryosuke Miura, and Makoto Shiozawa
- Subjects
Male ,Drug ,Pediatrics ,medicine.medical_specialty ,media_common.quotation_subject ,Atomoxetine Hydrochloride ,Drug Prescriptions ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Retrospective survey ,Outpatients ,medicine ,Humans ,Attention deficit hyperactivity disorder ,Medical prescription ,Child ,General Psychology ,Retrospective Studies ,media_common ,business.industry ,Atomoxetine ,General Medicine ,medicine.disease ,030227 psychiatry ,Guanfacine ,Psychiatry and Mental health ,Pharmaceutical Preparations ,Attention Deficit Disorder with Hyperactivity ,Methylphenidate ,Central Nervous System Stimulants ,Female ,Delivery system ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.
- Published
- 2021
- Full Text
- View/download PDF